Synaffix B.V. announced today the expansion of its Scientific Advisory Board (SAB) with the addition of Dr. John M. Lambert, the former Chief Scientific Officer of ImmunoGen, Inc.
Dr.... read more
Synaffix B.V. announced today the expansion of its Scientific Advisory Board (SAB) with the addition of Dr. John M. Lambert, the former Chief Scientific Officer of ImmunoGen, Inc.
Dr.... read more
AstraZeneca and MedImmune, announced on 5/11/18 top-line results from the GALATHEA Phase III trial for Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive pulmonary... read more
Krystal Biotech Inc., (“Krystal”) (NASDAQ:KRYS), announced on 5/11/18 that the first patient has been dosed in the Phase 1/2, first in-human trial of KB103, a first-in-class topical gene therapy... read more
Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced on 5/11/18 that the U.S. Food and Drug Administration’s... read more
